Prevalence and factors associated with cognitive deficit in women with gynecologic malignancies

Anne R. Van Arsdale, Debra Rosenbaum, Gurpreet Kaur, Priya Pinto, Dennis Yi-Shin Kuo, Ruben Barrera, Gary L. Goldberg, Nicole S. Nevadunsky

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: Cognitive impairment has implications in counseling, treatment, and survivorship for women with gynecologic malignancies. The purpose of our study was to evaluate the prevalence and risk factors associated with cognition in women with gynecologic malignancies. Methods: After Institutional Review Board approval, 165 women at an urban ambulatory gynecologic oncology facility were queried using a Montreal Cognitive Assessment (MoCA), Wong-Baker pain scale, neuropathy scale, Patient Health Questionnaire 9 (PHQ-9) Depression Scale, and Generalized Anxiety Disorder Scale (GAD 7). Univariate and multivariate analyses were utilized to evaluate the association of cognitive deficit with age, education, race/ethnicity, disease site, stage, treatment, pain, neuropathy, anxiety, and depression. Results: The mean MoCA score for the entire cohort was 24.1 (range 13-30.) 24% of patients had MoCA scores less than 22. Low scores (

Original languageEnglish (US)
JournalGynecologic Oncology
DOIs
StateAccepted/In press - Oct 19 2015

Fingerprint

Depression
Pain
Neoplasms
Research Ethics Committees
Anxiety Disorders
Cognition
Counseling
Multivariate Analysis
Survival Rate
Anxiety
Education
Health
Therapeutics
Cognitive Dysfunction
Surveys and Questionnaires

Keywords

  • Anxiety
  • Cognition
  • Depression
  • Gynecologic malignancies
  • Pain
  • Quality of life

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Prevalence and factors associated with cognitive deficit in women with gynecologic malignancies. / Van Arsdale, Anne R.; Rosenbaum, Debra; Kaur, Gurpreet; Pinto, Priya; Kuo, Dennis Yi-Shin; Barrera, Ruben; Goldberg, Gary L.; Nevadunsky, Nicole S.

In: Gynecologic Oncology, 19.10.2015.

Research output: Contribution to journalArticle

@article{0f2eda51fd444686a126ef464ec15b4c,
title = "Prevalence and factors associated with cognitive deficit in women with gynecologic malignancies",
abstract = "Objective: Cognitive impairment has implications in counseling, treatment, and survivorship for women with gynecologic malignancies. The purpose of our study was to evaluate the prevalence and risk factors associated with cognition in women with gynecologic malignancies. Methods: After Institutional Review Board approval, 165 women at an urban ambulatory gynecologic oncology facility were queried using a Montreal Cognitive Assessment (MoCA), Wong-Baker pain scale, neuropathy scale, Patient Health Questionnaire 9 (PHQ-9) Depression Scale, and Generalized Anxiety Disorder Scale (GAD 7). Univariate and multivariate analyses were utilized to evaluate the association of cognitive deficit with age, education, race/ethnicity, disease site, stage, treatment, pain, neuropathy, anxiety, and depression. Results: The mean MoCA score for the entire cohort was 24.1 (range 13-30.) 24{\%} of patients had MoCA scores less than 22. Low scores (",
keywords = "Anxiety, Cognition, Depression, Gynecologic malignancies, Pain, Quality of life",
author = "{Van Arsdale}, {Anne R.} and Debra Rosenbaum and Gurpreet Kaur and Priya Pinto and Kuo, {Dennis Yi-Shin} and Ruben Barrera and Goldberg, {Gary L.} and Nevadunsky, {Nicole S.}",
year = "2015",
month = "10",
day = "19",
doi = "10.1016/j.ygyno.2016.03.001",
language = "English (US)",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Prevalence and factors associated with cognitive deficit in women with gynecologic malignancies

AU - Van Arsdale, Anne R.

AU - Rosenbaum, Debra

AU - Kaur, Gurpreet

AU - Pinto, Priya

AU - Kuo, Dennis Yi-Shin

AU - Barrera, Ruben

AU - Goldberg, Gary L.

AU - Nevadunsky, Nicole S.

PY - 2015/10/19

Y1 - 2015/10/19

N2 - Objective: Cognitive impairment has implications in counseling, treatment, and survivorship for women with gynecologic malignancies. The purpose of our study was to evaluate the prevalence and risk factors associated with cognition in women with gynecologic malignancies. Methods: After Institutional Review Board approval, 165 women at an urban ambulatory gynecologic oncology facility were queried using a Montreal Cognitive Assessment (MoCA), Wong-Baker pain scale, neuropathy scale, Patient Health Questionnaire 9 (PHQ-9) Depression Scale, and Generalized Anxiety Disorder Scale (GAD 7). Univariate and multivariate analyses were utilized to evaluate the association of cognitive deficit with age, education, race/ethnicity, disease site, stage, treatment, pain, neuropathy, anxiety, and depression. Results: The mean MoCA score for the entire cohort was 24.1 (range 13-30.) 24% of patients had MoCA scores less than 22. Low scores (

AB - Objective: Cognitive impairment has implications in counseling, treatment, and survivorship for women with gynecologic malignancies. The purpose of our study was to evaluate the prevalence and risk factors associated with cognition in women with gynecologic malignancies. Methods: After Institutional Review Board approval, 165 women at an urban ambulatory gynecologic oncology facility were queried using a Montreal Cognitive Assessment (MoCA), Wong-Baker pain scale, neuropathy scale, Patient Health Questionnaire 9 (PHQ-9) Depression Scale, and Generalized Anxiety Disorder Scale (GAD 7). Univariate and multivariate analyses were utilized to evaluate the association of cognitive deficit with age, education, race/ethnicity, disease site, stage, treatment, pain, neuropathy, anxiety, and depression. Results: The mean MoCA score for the entire cohort was 24.1 (range 13-30.) 24% of patients had MoCA scores less than 22. Low scores (

KW - Anxiety

KW - Cognition

KW - Depression

KW - Gynecologic malignancies

KW - Pain

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=84960984217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960984217&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2016.03.001

DO - 10.1016/j.ygyno.2016.03.001

M3 - Article

C2 - 26946094

AN - SCOPUS:84960984217

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

ER -